OUR FOCUS ON INNOVATIVE MEDICINE
We have developed expertise through our comprehensive study of industry and academic efforts in targeted areas of significant innovation. By focusing our energies, we believe we can add more value to entrepreneurs and scientists. Our current focus areas include both technology platforms and disease areas, and include:
OUR IN-DEPTH INSIGHT
THE FUTURE LOOKS BRIGHT
Thanks to the genome, drug innovation is clearly accelerating.
We are living in the middle of a cancer therapy revolution.
Drugs in the
The number of new patents has inflected upward. This is translating into both more and better drugs in the pipeline.
Cancer kills over 1 million people each year in the US and Europe. The coming decade could drop this number by over a third.
New therapeutic classes like checkpoint inhibitors, cell therapy, gene therapy, and oligos should lead to substantial new revenues.
We expect half a trillion of new value creation for small and large companies in biotech and pharma.
OUR SUCCESSFUL PARTNERSHIPS
We support companies through the ups and downs of the often challenging journey to bring therapies to patients.
- Jon Stonehouse
Chief Executive Officer, BioCryst Pharmaceuticals"Rod dug in our company when many other investors disappeared. He did the work and realized BioCryst’s potential for treating rare diseases such as HAE long before others did."
- Joe Kiani
Founder, Chairman & CEO, Masimo"RTW does deeper diligence than nearly any other investor I know. RTW’s research and guidance in the early days of Rainbow and noninvasive hemoglobin was a valuable resource. They helped us understand the opportunity and have been a trusted partner since."
- Tim Van Hauwermeiren
Chief Executive Officer, Argenx"The RTW Team spotted the argenx investment opportunity ahead of the curve and rapidly developed from an investor to a loyal partner. Their data based approach and desire to understand resonates very well with our company culture."
- John Maraganore, PhD
Chief Executive Officer, Alnylam Pharmaceuticals"We view the team at RTW with highest regard. They believed in Alnylam's potential when the rest of the world was skeptical."
- Sukumar Nagendran, MD
Chief Medical Officer, Avexis"RTW uses scientific and clinical acumen to decipher critical investments. Rod and Piratip were excellent strategic partners who had the foresight to invest in Avexis."
- George F. Tidmarsh, MD, PhD
Chief Executive Officer, La Jolla Pharmaceutical"Rod has been with us from the very beginning when we restarted LJPC. His research, insights and support have been critical in making our journey a success."
We believe biotech will be a key value creator over the next decade.
Contact us to learn more about RTW’s expertise, insight and experience in identifying and working with companies focused in areas of breakthrough innovation.